Cantargia reported positive results from the phase 1/2A CANFOUR trial evaluating CAN04 in combination with chemotherapy in patients with metastatic pancreatic cancer and metastatic non-small cell lung cancer (NSCLC). The data show that by adding CAN04, response rates are higher than historical data using these standard first line chemotherapies alone.
Canfour is an open label, dose escalation trial designed to evaluate CAN04 both as a monotherapy and in combination with standard of care treatment in patients with solid tumors. In the combination arm to date, 4 patients with metastatic pancreatic cancer and 4 with metastatic NSCLC have initiated CAN04 therapy at 5 mg/kg, and 6 pancreatic cancer patients have started at 7.5 mg/kg. Four (4) out of 7 evaluable patients with metastatic pancreatic cancer and 2 out of 3 patients with metastatic NSCLC, including 1 patient with complete response (CR), had objective responses. The most common adverse effect associated with CAN04 was low-grade infusion related reaction during the first infusion. Besides this side effect, the adverse events observed are those expected with chemotherapy. The most common grade 3 and 4 toxicities include neutropenia, thrombocytopenia, fatigue. The completion of recruitment is expected early Q2 2020 (pancreatic cancer) and early Q3 2020 (NSCLC).
The antibody CAN04 binds IL1RAP with high affinity and functions through both ADCC and blockade of IL-1α and IL-1β signaling. CAN04 works both by stopping tumor inflammation and by binding to the cancer cells, which the immune system’s killer cells are then stimulated to destroy.